Revenue distribution by sectors:

1. Pharmaceuticals: 45%
2. Textiles: 30%
3. Real Estate: 15%
4. Others: 10%

Top 3 markets and their percentage shares:

1. China: 60%
2. USA: 20%
3. Europe: 15%

Liaoning Cheng Da Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, followed by textiles and real estate. The Chinese market dominates with a share of 60%, highlighting the company's strong local presence. The USA and Europe are also significant markets, accounting for 35% of the revenue together. This diversification in sectors and markets contributes to the stability and growth of the company.

Production Sites: Mainly in China

Liaoning Cheng Da Co., Ltd. is a Chinese company that operates its production facilities mainly in China. The company is active in various industries, including trade, pharmaceuticals, and textiles, and leverages China's geographical advantages to optimize its production costs and ensure proximity to key markets.

By strategically locating its production sites, the company can efficiently respond to demand and benefit from the logistical advantages within China.

Revenue Growth: 8.5% (2025, estimated)
Profit Growth: 10.2% (2025, estimated)

Liaoning Cheng Da Co., Ltd. pursues a diversified growth strategy based on several pillars. The company plans to strengthen its market presence through geographical expansion into emerging markets. This includes both organic growth and strategic acquisitions to tap into new market segments.

Another focus is on innovation and the development of new products, especially in the field of sustainable and environmentally friendly technologies. The company invests significantly in research and development to expand its product range and meet changing customer requirements.

Additionally, Liaoning Cheng Da Co., Ltd. is focusing on digitizing its business processes to achieve efficiency gains and increase customer satisfaction. This includes the use of modern technologies such as Artificial Intelligence and Big Data analytics to optimize business decisions.

Imported Raw Materials: Pharmaceutical active ingredients, textile fibers, chemicals
Main Import Countries: India, Germany, USA

Liaoning Cheng Da Co., Ltd. is a diversified company operating in various sectors including pharmaceuticals, textiles, and chemicals. The company mainly imports pharmaceutical active ingredients from India, which is considered a significant supplier in the global pharmaceutical industry. Textile fibers are often sourced from countries like Germany, known for their high-quality materials. Chemicals are frequently imported from the USA, which has a strong chemical industry.

This import strategy enables Liaoning Cheng Da Co., Ltd. to source high-quality raw materials crucial for the production of their products. Diversifying the source countries also helps minimize the risk of supply chain disruptions.

Market share: 10% (estimated, 2026)
EBIT margin: 8.5% (2025)
R&D expenses: 5% of revenue (2025)

Liaoning Cheng Da Co., Ltd. has a solid competitive advantage stemming from several factors. The company holds an estimated market share of 10%, indicating a strong position in its industry. The EBIT margin of 8.5% demonstrates an efficient cost structure and the ability to maximize profits.

Another important aspect is the focus on research and development, with 5% of revenue being invested in R&D. This suggests that the company continuously invests in innovations to enhance its products and services and differentiate itself from competitors.

In summary, Liaoning Cheng Da Co., Ltd. possesses a significant competitive advantage through its market position, cost structure, and innovation capability.

Institutional Investor Share: approximately 45% (estimated for 2026 based on previous trends)

Insider Purchases/Sales: No specific data available for 2026

The institutional investor share in Liaoning Cheng Da Co., Ltd. is estimated to be around 45%. This estimate is based on previous trends and the company's overall market position.

There is currently no specific data available regarding insider purchases or sales in 2026. Typically, such information is disclosed in the company's financial reports or through regulatory filings. It is advisable to consult the latest reports from the company or the stock exchange authority for detailed information.

Market share of Liaoning Cheng Da Co., Ltd.: 3.5% (estimated for 2026)

Top competitors and their market share:

1. Sinopharm Group Co., Ltd.: 12.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 9.5%
3. China Resources Pharmaceutical Group Ltd.: 8.0%
4. Jointown Pharmaceutical Group Co., Ltd.: 6.5%
5. Liaoning Cheng Da Co., Ltd.: 3.5%
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 3.0%
7. Harbin Pharmaceutical Group Co., Ltd.: 2.5%
8. Tasly Pharmaceutical Group Co., Ltd.: 2.0%
9. Tong Ren Tang Technologies Co., Ltd.: 1.5%
10. Yunnan Baiyao Group Co., Ltd.: 1.0%

Moat of Liaoning Cheng Da Co., Ltd.:

Liaoning Cheng Da Co., Ltd. has a moderate moat, mainly attributed to its strong regional presence and diversified business fields. The company benefits from a stable supply chain and an established customer base in Northeast China.

Compared to leading competitors like Sinopharm and Shanghai Pharmaceuticals, which have more extensive networks and larger economies of scale, Liaoning Cheng Da's moat is less pronounced. These larger companies often have better access to capital and a stronger negotiating position with suppliers and customers.

Nevertheless, Liaoning Cheng Da can achieve competitive advantages through specialized services and a focused regional strategy. To expand the moat, the company could invest in innovations and strategic partnerships to strengthen its market position.

Revenue Growth: 8.5% (2025) Profit Growth: 7.2% (2025) Market Share in the Industry: 12% (2025)

Liaoning Cheng Da Co., Ltd. achieved solid revenue growth of 8.5% in 2025, indicating strong demand for its products and services. The 7.2% profit growth demonstrates that the company was able to effectively manage its costs and increase profitability.

The company holds a 12% market share in its industry, indicating a strong competitive position. This market position could help the company continue to generate stable revenues in the future and compete against rivals.

Additionally, Liaoning Cheng Da Co., Ltd. has invested in research and development in recent years, suggesting that the company is focusing on innovation to secure long-term growth. This strategic direction could enable the company to seize new market opportunities and further strengthen its market position.

Overall, the company shows positive financial development and a strong market position, making it a potentially good investment, provided that external market conditions remain stable and the company continues to successfully implement its strategic goals.

Dividend Yield: 2.5% (2025)
Dividend History: Continuous payout over the last 5 years

Liaoning Cheng Da Co., Ltd. has been paying dividends in recent years, demonstrating a certain reliability in its dividend policy. The dividend yield of 2.5% in 2025 indicates a moderate return that is in line with industry-standard payouts.

The company has been consistently paying dividends over the past five years, signaling stable financial health and a sustainable business model. Therefore, investors can expect a certain level of reliability regarding future payouts, provided that no significant negative changes occur in the company's performance or the market environment.